Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

DIDANOSINE CRS (10 MG)

DIDANOSINE CRS (10 MG)

69655-05-6

DISCOVER
DIDANOSINE FOR SYSTEM SUITABILITY CRS (10 MG)

DIDANOSINE FOR SYSTEM SUITABILITY CRS (10 MG)

69655-05-6

DISCOVER
DIDANOSINE IMPURITY A CRS (20MG)

DIDANOSINE IMPURITY A CRS (20MG)

68-94-0

DISCOVER
DIDANOSINE IMPURITY G CRS (10MG)

DIDANOSINE IMPURITY G CRS (10MG)

4097-22-7

DISCOVER
FLUNIXIN MEGLUMINE CRS (10 MG)

FLUNIXIN MEGLUMINE CRS (10 MG)

42461-84-7

DISCOVER
FLUNIXIN IMPURITY B CRS (15 MG)

FLUNIXIN IMPURITY B CRS (15 MG)

54396-44-0

DISCOVER
FLUNIXIN IMPURITY C CRS (55 MG)

FLUNIXIN IMPURITY C CRS (55 MG)

1452-94-4

DISCOVER
HYDROMORPHONE HYDROCHLORIDE CRS - * NARC (10 MG)

HYDROMORPHONE HYDROCHLORIDE CRS - * NARC (10 MG)

71-68-1

DISCOVER
Hyoscine butylbromide impurity E 10 mg

Hyoscine butylbromide impurity E 10 mg

NA

DISCOVER
HYOSCINE HYDROBROMIDE IMPURITY B CRS (10 MG)

HYOSCINE HYDROBROMIDE IMPURITY B CRS (10 MG)

NA

DISCOVER
HYOSCYAMINE IMPURITY E CRS (15 MG)

HYOSCYAMINE IMPURITY E CRS (15 MG)

NA

DISCOVER
KETAMINE HYDROCHLORIDE CRS - * NARC (15 MG)

KETAMINE HYDROCHLORIDE CRS - * NARC (15 MG)

1867-66-9

DISCOVER